Recent advances and applications of peptide–agent conjugates for targeting tumor cells

Background Cancer, being a complex disease, presents a major challenge for the scientific and medical communities. Peptide therapeutics have played a significant role in different medical practices, including cancer treatment. Method This review provides an overview of the current situation and pote...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Journal of cancer research and clinical oncology Ročník 149; číslo 16; s. 15249 - 15273
Hlavní autori: Alamdari-palangi, Vahab, Jaberi, Khojaste Rahimi, Shahverdi, Mahshid, Naeimzadeh, Yasaman, Tajbakhsh, Amir, Khajeh, Sahar, Razban, Vahid, Fallahi, Jafar
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Berlin/Heidelberg Springer Berlin Heidelberg 01.11.2023
Springer Nature B.V
Predmet:
Angiogenesis
antineoplastic activity
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Antitumor activity
Apoptosis
Autophagy
Bioavailability
Cancer Research
Cancer therapies
cancer therapy
Cationic peptides
Cell Death
Cell membranes
Chemotherapy
Clinical trials
Cytochrome c
Cytotoxic agents
Cytotoxicity
drug therapy
Hematology
Humans
Immune system
Immunosuppressive agents
Internal Medicine
leukemia
Lysis
mechanism of action
Medicine
Medicine & Public Health
Necrosis
Neoplasms - pathology
Oncology
Peptides
Peptides - pharmacology
Peptides - therapeutic use
Radioisotopes
Review
Tumor cells
Vaccines
Vaccines, Subunit - pharmacology
Vaccines, Subunit - therapeutic use
Peptide–drug conjugates
Tumor
Treatment
Peptide
Peptide vaccines
ISSN:0171-5216, 1432-1335, 1432-1335
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Background Cancer, being a complex disease, presents a major challenge for the scientific and medical communities. Peptide therapeutics have played a significant role in different medical practices, including cancer treatment. Method This review provides an overview of the current situation and potential development prospects of anticancer peptides (ACPs), with a particular focus on peptide vaccines and peptide-drug conjugates for cancer treatment. Results ACPs can be used directly as cytotoxic agents (molecularly targeted peptides) or can act as carriers (guiding missile) of chemotherapeutic agents and radionuclides by specifically targeting cancer cells. More than 60 natural and synthetic cationic peptides are approved in the USA and other major markets for the treatment of cancer and other diseases. Compared to traditional cancer treatments, peptides exhibit anticancer activity with high specificity and the ability to rapidly kill target cancer cells. ACP's target and kill cancer cells via different mechanisms, including membrane disruption, pore formation, induction of apoptosis, necrosis, autophagy, and regulation of the immune system. Modified peptides have been developed as carriers for drugs, vaccines, and peptide–drug conjugates, which have been evaluated in various phases of clinical trials for the treatment of different types of solid and leukemia cancer. Conclusions This review highlights the potential of ACPs as a promising therapeutic option for cancer treatment, particularly through the use of peptide vaccines and peptide–drug conjugates. Despite the limitations of peptides, such as poor metabolic stability and low bioavailability, modified peptides show promise in addressing these challenges. Graphical abstract Various mechanism of action of anticancer peptides. Modes of action against cancer cells including: inducing apoptosis by cytochrome c release, direct cell membrane lysis (necrosis), inhibiting angiogenesis, inducing autophagy-mediated cell death and immune cell regulation.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0171-5216
1432-1335
1432-1335
DOI:10.1007/s00432-023-05144-9